

File reference	W17FOI163
Key words	Non-Small Cell Lung Cancer
Date of release	25/04/2017
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

- 1. Within your health trust how many patients are currently [within the past 6 months] being treated with a chemotherapy agent [not including surgery/radiotherapy only];**

For the period October 1st 2016 to February 28th 2017 there were a total of 1,207 distinct patients who received chemotherapy at Plymouth Hospitals NHS Trust (PHNT) – these 1,207 will have attended on multiple occasions during that period for chemo treatment.

- 2. All Non-Small Cell Lung Cancer patients
Patients with Non-Small Cell Lung Cancer (NSCLC) Stage IIIB**/IV**
(Stage 3b/4). Of the NSCLC patients, please state the number of patients currently [within the past 6 months] being treated with the following therapies;**

PHNT does treat patients with NSCLC.

<u>Treatment</u>	<u>Number of Patients</u>
Afatinib (Giotrif)	Not applicable
Ceritinib (Zykadia)	Not applicable
Crizotinib (Xalkori)	Not applicable
Erlotinib (Tarceva)	Not applicable
Gefitinib (Iressa)	Not applicable
Nitendaninb + docetaxel	Not applicable
Nivolumab (Opdivo)	Not applicable
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	Not applicable
Pembrolizumab (Keytruda)	Not applicable

Gemcitabine mono or in combination with carboplatin / cisplatin	Not applicable
Paclitaxel mono or in combination with carboplatin / cisplatin	Not applicable
Doxetaxel mono or in combination with carboplatin / cisplatin	Not applicable
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	Not applicable

2a. If your trust does not treat these cancers and you refer your patients to another trust, please state which trust?

PHNT does treat patients with NSCLC.

3. Within your health trust how many patients are currently [within the past 6 months] diagnosed with Urothelial cancer? All Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients (TREATED or UNTREATED); Metastatic* or locally advanced* Urothelial cancer (UCC, also transitional cell carcinoma or TCC) patients

For the period October 1st 2016 to February 28th 2017 there were a total of 115 distinct patients who were inpatients at PHNT where UCC / TCC was recorded as a diagnosis in any coding position during their spell with PHNT who had NOT had a previous spell at PHNT during the last 15 years where UCC / TCC coding was present. Please note we cannot safely provide a definitive answer as to the number diagnosed during the last 6 months as this is not always recorded electronically and also some of these 115 might have been previously diagnosed at another provider or before the year 2000.

3a. Of these patients (metastatic/locally advanced UCC), please state the number of patients currently [within the past 6 months] being treated with the following therapies;

<u>Treatment</u>	<u>Number of Patients</u>
------------------	---------------------------

Cisplatinum single agent	The Trust cannot provide answers to your questions about drug usage. The Trust cannot provide a definitive answer to question 3 and to examine patient records would exceed the appropriate limit of 18 hours for this question alone. Please see legal notes
Cisplatinum in combination with another agent	As above
Carboplatinum single agent	As above
Carboplatinum in combination with another agent	As above
Any other chemo regimen without cisplatinum or carboplatinum	As above

*TNM staging for metastatic Urothelial Cancer = Any T, any N, M1

*TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0

**TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0

**TNM staging for Stage IV NSCLC = Any T, any N, M1

Legal notes

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it does not hold the information requested in any collated format. Individual records of how someone was treated and their conditions would be held in clinical records, but the Trust could not locate, extract and collate such information as requested within the limitations of the Act. It is therefore considered exempt from supply in accordance with section 12(1) of the Act – Request exceeds the appropriate limit by virtue of section 13.(1)(a) – The Cost of Compliance exceeds the appropriate limit.

Attachments included: No